Chardan Capital Maintains Buy on Femasys, Lowers Price Target to $12
Chardan Capital analyst Keay Nakae maintains Femasys (NASDAQ:FEMY) with a Buy and lowers the price target from $15 to $12.
Femasys Q3 EPS $(0.25) Down From $(0.19) YoY, Sales $347.46K Up From $269.58K YoY
Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.25) per share. This is a 31.58 percent decrease over losses of $(0.19) per share from the same period last year. The company reported $347.46 thousand in sales this
Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday
Gainers
ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate Cancer Foundation Scientific Retreat.
Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From Friday
Gainers
Innovative Eyewear, Inc. (NASDAQ: LUCY) climbed 61.4% to close at $2.63 on abnormally-high volume. The company released its October investor presentation yesterday.
Why Aehr Test Systems Shares Are Trading Higher By Over 19%, Here Are 51 Stocks Moving In Friday’s Mid-Day Session
Gainers
Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 108% to $3.3943 on abnormally-high volume. The company released its October investor presentation yesterday.
Femasys Inc. Announces Enrollment Completion For Stage 2 Study Of FemBloc For Permanent Birth Control
Femasys Inc. (NASDAQ:FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health,
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 402 companies made new 52-week lows.
